Hosted on MSN3h
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says MizuhoMizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...
Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...
Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...
Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising Phase 2 results, Cybin’s PARADIGM program has begun with significant funding ...
In a paper published in Science Bulletin, a Chinese team of scientists made a significant breakthrough in major depressive ...
Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...
The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement ...
Dogs 4 Valor, operated through the Olathe, Kansas-based organization called The Battle Within, helps retired veterans and ...
Neuronetics ( (STIM) ) has released its Q3 earnings. Here is a breakdown of the information Neuronetics presented to its investors.
Xenon (XENE) has released an update. Xenon Pharmaceuticals reported an optimistic outlook for its epilepsy and major depressive disorder ...
Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...
Clearance paves the way for the use of the TMS technology to treat patients with major depressive disorder (MDD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback